Clinical Trials Browser

Phase 2 × Adenocarcinoma of Lung × anetumab ravtansine × Clear all

NCT02839681 2019-05-21

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Phase 2 Terminated

2 enrolled 12 charts

Adenocarcinoma of Lung, Lung Neoplasms